NCT07602907 Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study Status RECRUITING Phase PHASE2
NCT07483307 A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer Status RECRUITING Phase PHASE2
NCT07466927 Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases Status NOT_YET_RECRUITING Phase PHASE2
NCT07396454 Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib Status RECRUITING Phase PHASE2
NCT07379918 Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer Status RECRUITING Phase N/A
NCT07366112 CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment Status RECRUITING Phase PHASE2
NCT07281833 Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment Status RECRUITING Phase PHASE3
NCT07227831 A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer Status NOT_YET_RECRUITING Phase NA
NCT07198724 ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06999187 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas Status RECRUITING Phase PHASE1
NCT06993506 Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer Status RECRUITING Phase N/A
NCT06970912 ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer Status RECRUITING Phase PHASE2
NCT06774027 Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer Status RECRUITING Phase N/A
NCT06756932 BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer Status RECRUITING Phase PHASE1
NCT06691035 Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06678269 A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer Status RECRUITING Phase PHASE1
NCT06650423 Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer Status RECRUITING Phase N/A